• Akoya Biosciences Inc AKYA.OQ reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -48 cents. The mean expectation of eight analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -23 cents to -17 cents per share.

• Revenue fell 9.3% to $16.64 million from a year ago; analysts expected $19.95 million.

• Akoya Biosciences Inc's reported EPS for the quarter was a loss of 32 cents​.

• The company reported a quarterly loss of $15.65 million.

• Akoya Biosciences Inc shares had fallen by 20.9% this quarter and lost 52.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 3.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "hold"

• Wall Street's median 12-month price target for Akoya Biosciences Inc is $3.00

This summary was machine generated from LSEG data May 12 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)